Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...
A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...
GlobalData on MSN1d
Regeneron makes second bid for blood cancer therapy approvalThe FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
Regeneron last year won European Commission approval of odronextamab as Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...
The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...
The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for review the resubmission of the ...
For deeper insights into Regeneron's financial health and growth potential, InvestingPro subscribers can access comprehensive analysis and 8 additional ProTips. Follicular lymphoma, a common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback